Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04186845 · ClinicalTrials.gov registry record · Phase 3
Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence
A Phase 3 study, sponsored by Blue Earth Diagnostics.
- Completed
- Registry status
- Phase 3
- Development phase
- 391
- Enrollment target
NCT04186845 is a Phase 3 study that has completed, run by Blue Earth Diagnostics. The registered enrollment target is 391 participants.
The verdict
NCT04186845, a Phase 3 study, has completed, sponsored by Blue Earth Diagnostics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 391 participants
- Enrollment target
Study Summary
A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) ligand in men with suspected prostate cancer recurrence based on elevated Prostate-specific antigen (PSA) following prior therapy.
Interventions
- DRUG rhPSMA-7.3 (18F) Injection
- DIAGNOSTIC_TEST Positron emission tomography scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 391 participants |
| Start Date | 2020-05-04 |
| Est. Completion | 2021-04-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04186845
The ClinicalTrials.gov registry entry for NCT04186845 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 391 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Blue Earth Diagnostics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rhPSMA-7.3 (18F) Injection is the first listed.
NCT04186845 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04186845 about?
NCT04186845 is a clinical study titled "Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence". A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) ligand in men with suspected prostate cancer recurrence based on elevated Prostate-specific antigen (PSA) following prior therapy...
What is the current status of trial NCT04186845?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 391 participants. The study started on 2020-05-04. Estimated completion is 2021-04-28.
What interventions are being tested in trial NCT04186845?
The interventions under investigation include: rhPSMA-7.3 (18F) Injection (DRUG), Positron emission tomography scan (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04186845?
This trial is sponsored by Blue Earth Diagnostics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.